Matthew Perkins
A5029603803- Alzheimer's disease research and treatments
- Genetic Neurodegenerative Diseases
- Neurological diseases and metabolism
- Parkinson's Disease Mechanisms and Treatments
- Genomics and Rare Diseases
- Amyotrophic Lateral Sclerosis Research
- Diet and metabolism studies
- Dementia and Cognitive Impairment Research
- Bioinformatics and Genomic Networks
- Genetic Associations and Epidemiology
- Nuclear Receptors and Signaling
- Hereditary Neurological Disorders
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Mitochondrial Function and Pathology
- Genetics, Aging, and Longevity in Model Organisms
Michigan United
2019-2021
University of Michigan
2019-2021
Columbia University Irving Medical Center
2020
Neuroinflammation, particularly that involving reactive microglia, the brain's resident immune cells, is implicated in pathogenesis of major neurodegenerative diseases. However, early markers this process are high demand. Multiple studies have reported changes ribosomal protein (RP) expression during neurodegeneration, but significance these remains unclear. Ribosomes evolutionarily conserved synthesizing machines, and although commonly viewed as invariant, accumulating evidence suggest...
The common neurodegenerative syndromes exhibit age-related incidence, and many Mendelian diseases penetrance. Mutations slowing aging retard age related pathologies. To assess whether delayed retards the effects of a mutant allele causing Huntington's disease (HD)-like syndrome, we generated compound mice, placing dominant HD knock-in polyglutamine onto slow-aging Snell dwarf genotype. genotype did not affect huntingtin protein expression. Bigenic control mice were evaluated prospectively...
Abstract Up to 80% of Parkinson's disease patients develop dementia, but time dementia varies widely from motor symptom onset. Dementia with Lewy bodies presents clinical features similar Parkinson’s cognitive impairment precedes or coincides It remains controversial whether and are distinct conditions represent part a spectrum. The biological mechanisms underlying heterogeneity, in particular the development remain poorly understood, will likely be key understanding pathways and,...
Abstract Lewy body dementia is the second most common neurodegenerative after Alzheimer’s disease. Disease-modifying therapies for this disabling neuropsychiatric condition are critically needed. To identify drugs associated with risk of developing dementia, we performed a population-based case–control study 148 170 US Medicare participants diagnosed between 1 January 2008 and 31 December 2014 253 043 frequency-matched controls. We estimated odds ratios 95% confidence intervals association...
Abstract The genetic basis of Lewy body dementia (LBD) is not well understood. Here, we performed whole-genome sequencing in large cohorts LBD cases and neurologically healthy controls to study the architecture this understudied form generate a resource for scientific community. Genome-wide association analysis identified five independent risk loci, whereas genome-wide gene-aggregation tests implicated mutations gene GBA . Genetic scores demonstrate that shares profiles pathways with...